Skip to main content

Sleep Intervention to Enhance Cognitive Status and Reduce Beta-Amyloid (SIESTA)


This study will investigate the effects of cognitive behavioral training for insomnia (CBT-I) on improving cognitive function and reducing beta-amyloid accumulation in older adults with insomnia. Beta-amyloid is a protein that builds up in the brains of people with Alzheimer's disease.

Minimum Age Maximum Age Gender Healthy Volunteers
60 Years 85 Years All Yes
August 27, 2019
September 2020

  • Difficulty falling asleep, maintaining sleep, or waking up too early at least 3 nights a week for the past 6 months
  • Insomnia Severity Index score of 10 or greater 
  • Mini-Mental State Examination score of 25 or greater
  • Dementia Screening Interview score of 2 or less

  • Known untreated sleep disorder, such as sleep apnea or restless leg syndrome
  • Currently taking benzodiazepines, nonbenzodiazepines, melatonin supplements, or agonists for insomnia
  • Severe depression (Patient Health Questionnaire score of 15 or more) or suicidal ideation
  • History of drug or alcohol abuse in past 2 years
  • History of a nervous system disorder, such as stroke or Parkinson's disease
  • Severe mental illness, such as schizophrenia or bipolar disorder
  • History of a learning disability or attention-deficit/hyperactivity disorder
  • Current or previous shift work
  • Currently or previously received CBT-I
  • Unable to hear at a conversational level
  • Failure of a near vision test

CBT-I therapy is designed to improve sleep by addressing the sleep environment, schedules, behaviors, and thoughts a person has. Participants will be randomly assigned to either one-on-one CBT-I training or to stretching and thinking activities for 6 weeks. Sessions will be 45 to 60 minutes long once per week. Participants in the CBT-I group will also maintain a sleep diary. A subgroup of CBT-I participants will undergo positron emission tomography imaging at the 1-year reassessment to examine the effects of training on reducing the accumulation of proteins associated with Alzheimer's disease.

Name City State Zip Status Primary Contact
University of Kansas Medical Center- Sleep, Health and Wellness Laboratory
Kansas City Kansas 66160 Recruiting Eryen Nelson, MPH

University of Kansas Medical Center

  • National Institute on Aging (NIA)
  • National Institutes of Health (NIH)

Name Role Affiliation
Catherine Siengsukon, PT, PhD Principal Investigator University of Kansas Medical Center

Name Phone Email
Eryen Nelson, MPH (913) 585-7349


SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid